Clinic
Saint Joseph Mercy Livingston Hospital
Saint Joseph Mercy Livingston Hospital was paid $18.28M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoSAINT JOSEPH MERCY LIVINGSTON HOSPITAL
HOWELL, MI 48843
HOWELL, MI 48843
33aNPI1093748642assigned 07/08/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$18.28M
24GClaims549,277
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Michigan
Rank by total paid#2 of 48
Median peer was paid$97K
This provider vs. median189×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GUSHO, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,456 | $2.13M | |
| 2019 | 66,272 | $2.10M | |
| 2020 | 60,664 | $2.07M | |
| 2021 | 86,098 | $3.00M | |
| 2022 | 97,827 | $3.14M | |
| 2023 | 104,898 | $3.26M | |
| 2024incomplete | 77,062 | $2.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 10,058 | 9,414 | $3.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 15,838 | 14,769 | $3.39M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 21,042 | 20,130 | $2.61M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.8% | 14,519 | 13,026 | $1.42M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 12,617 | 12,118 | $883K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 4,980 | 4,787 | $702K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 11,418 | 9,457 | $364K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 3,126 | 3,024 | $313K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 8,096 | 7,777 | $310K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 10,120 | 8,884 | $308K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 3,368 | 2,816 | $304K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 2,957 | 2,801 | $288K |
219 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 3,547 | $272K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 3,507 | $207K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 396 | $177K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 774 | $173K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,424 | $158K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,089 | $158K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,617 | $151K |
| 93975 | <1% | 1,123 | $138K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,543 | $136K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,155 | $118K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,958 | $114K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 857 | $107K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,092 | $101K |
| 80061 | Lipid panel | <1% | 9,206 | $101K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,746 | $99K |
| 76830 | Ultrasound, transvaginal | <1% | 1,655 | $96K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,559 | $82K |
| 80053 | Comprehensive metabolic panel | <1% | 30,536 | $80K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,551 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 1,680 | $68K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,566 | $62K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,883 | $62K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,404 | $60K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,749 | $59K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,075 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,284 | $54K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 129 | $54K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,861 | $51K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 226 | $46K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 2,449 | $40K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,224 | $30K |
| 70496 | <1% | 163 | $27K | |
| 82728 | <1% | 3,113 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,038 | $26K |
| 93971 | <1% | 465 | $25K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 52 | $25K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,303 | $24K |
| 85027 | <1% | 9,656 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,354 | $23K |
| 82607 | <1% | 2,458 | $22K | |
| 72100 | <1% | 980 | $20K | |
| 86900 | <1% | 1,729 | $19K | |
| 84466 | <1% | 2,272 | $17K | |
| 84439 | <1% | 4,008 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,376 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,359 | $17K |
| 76770 | <1% | 281 | $16K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 223 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,261 | $14K |
| 86780 | <1% | 1,536 | $12K | |
| 73630 | <1% | 1,748 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,383 | $12K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 865 | $11K |
| 83540 | <1% | 2,503 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,099 | $10K |
| 87340 | <1% | 1,620 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 74 | $9K |
| 73130 | <1% | 1,589 | $9K | |
| 73030 | <1% | 930 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,777 | $8K |
| 73610 | <1% | 1,313 | $8K | |
| 84702 | <1% | 4,169 | $8K | |
| 83735 | <1% | 13,476 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 965 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,099 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 708 | $6K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 54 | $6K |
| 86850 | <1% | 1,693 | $6K | |
| 85610 | <1% | 6,866 | $5K | |
| 74018 | <1% | 318 | $5K | |
| 83880 | <1% | 1,824 | $5K | |
| 71250 | <1% | 91 | $5K | |
| 84481 | <1% | 469 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $5K |
| 73110 | <1% | 1,025 | $5K | |
| 87428 | <1% | 129 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,219 | $5K |
| 73564 | <1% | 157 | $4K | |
| 80159 | <1% | 350 | $4K | |
| 86140 | <1% | 1,757 | $4K | |
| 82746 | <1% | 412 | $4K | |
| 76536 | <1% | 61 | $3K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 75 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 561 | $3K |
| 95806 | <1% | 40 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 212 | $3K |
| 84403 | <1% | 189 | $3K | |
| 73562 | <1% | 524 | $3K | |
| 70491 | <1% | 27 | $3K | |
| 81001 | <1% | 8,397 | $2K | |
| 86762 | <1% | 297 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 188 | $2K |
| 85652 | <1% | 2,079 | $2K | |
| 80076 | <1% | 2,297 | $2K | |
| 86803 | <1% | 286 | $2K | |
| 82570 | <1% | 660 | $2K | |
| 71271 | <1% | 38 | $2K | |
| 93017 | <1% | 64 | $2K | |
| 82043 | <1% | 598 | $2K | |
| 83690 | <1% | 7,488 | $2K | |
| 86901 | <1% | 1,906 | $2K | |
| 76642 | <1% | 51 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 38 | $2K |
| 85730 | <1% | 4,449 | $2K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 878 | $2K |
| 96376 | <1% | 2,851 | $2K | |
| 82950 | <1% | 546 | $1K | |
| 73502 | <1% | 135 | $1K | |
| 70486 | <1% | 52 | $1K | |
| 84703 | <1% | 6,388 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 468 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 941 | $1K |
| 82248 | <1% | 1,275 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 70 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 653 | $1K |
| 87081 | <1% | 1,169 | $1K | |
| 82784 | <1% | 123 | $994.60 | |
| 86039 | <1% | 126 | $902.98 | |
| 84146 | <1% | 66 | $877.74 | |
| 86364 | <1% | 72 | $876.92 | |
| 87186 | <1% | 500 | $851.28 | |
| 96367 | <1% | 21 | $778.26 | |
| 87077 | <1% | 411 | $741.98 | |
| 82670 | <1% | 38 | $732.21 | |
| 85379 | <1% | 2,772 | $731.02 | |
| 84100 | <1% | 618 | $719.66 | |
| 86592 | <1% | 253 | $718.67 | |
| 73080 | <1% | 138 | $713.48 | |
| 86258 | <1% | 40 | $664.78 | |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $611.69 |
| 86038 | <1% | 69 | $574.64 | |
| 81003 | <1% | 5,439 | $572.03 | |
| 82565 | <1% | 258 | $517.94 | |
| 84484 | <1% | 6,800 | $470.39 | |
| 82550 | <1% | 351 | $469.54 | |
| 76870 | <1% | 15 | $461.85 | |
| 84460 | <1% | 154 | $361.35 | |
| 0012A | <1% | 13 | $351.20 | |
| 73140 | <1% | 107 | $346.97 | |
| 85007 | <1% | 421 | $308.35 | |
| 73090 | <1% | 55 | $244.51 | |
| 84450 | <1% | 106 | $243.23 | |
| 0011A | <1% | 14 | $225.86 | |
| 87147 | <1% | 186 | $223.75 | |
| Q3014 | Telehealth originating site facility fee | <1% | 15 | $218.56 |
| 83605 | <1% | 3,733 | $208.91 | |
| 83001 | <1% | 15 | $208.02 | |
| 86431 | <1% | 53 | $206.30 | |
| 74022 | <1% | 266 | $197.75 | |
| 80055 | <1% | 51 | $161.04 | |
| 73590 | <1% | 86 | $147.90 | |
| 87088 | <1% | 38 | $134.53 | |
| 86200 | <1% | 12 | $106.26 | |
| 87040 | <1% | 445 | $102.45 | |
| 84630 | <1% | 13 | $102.28 | |
| 70498 | <1% | 133 | $100.63 | |
| 73552 | <1% | 12 | $98.90 | |
| 85651 | <1% | 55 | $75.62 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 16 | $64.64 |
| 82040 | <1% | 51 | $63.39 | |
| 90715 | <1% | 698 | $56.20 | |
| 87070 | <1% | 41 | $54.22 | |
| 83615 | <1% | 13 | $47.58 | |
| 82803 | <1% | 422 | $39.78 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 251 | $38.42 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,464 | $37.41 |
| 84156 | <1% | 13 | $32.89 | |
| 82947 | <1% | 13 | $27.96 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,864 | $22.09 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,252 | $13.84 |
| 87205 | <1% | 70 | $12.71 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,983 | $12.47 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,431 | $12.40 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,274 | $10.06 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,583 | $9.43 |
| 86308 | <1% | 12 | $8.24 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 732 | $7.54 |
| 84155 | <1% | 13 | $7.31 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,989 | $6.11 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,033 | $3.21 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,965 | $3.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,560 | $1.38 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 526 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,621 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,046 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,060 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 49 | $0.00 |
| 29125 | 0% | 72 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 310 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 74 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 12 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 42 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 13 | $0.00 |
| 12011 | 0% | 13 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 14 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 116 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,198 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,267 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 1,585 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 17 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,580 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,827 | $0.00 |
| 83520 | 0% | 965 | $0.00 | |
| 12001 | 0% | 149 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 83 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,031 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 377 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 225 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 83 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 85 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 183 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 87 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 24 | $0.00 |
| 87808 | 0% | 38 | $0.00 | |
| 12002 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 320 | $0.00 |
| 99156 | 0% | 15 | $0.00 | |
| 94760 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUSHO, MICHAEL (REGIONAL CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.